EHMT1

Across TCGA pan-cancer cohorts, EHMT1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EHMT1 data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EHMT1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EHMT1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where EHMT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.715	0.928	.006	10	view →
CCRCC	DFS	Quartile	III,IV	0.870	0.416	.025	9	view →
LUAD	DFS	Quartile	III,IV	1.000	0.602	.006	8	view →
LSCC	OS	Tertile	II,III,IV	0.889	0.590	.028	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

EHMT1–PDAC (OS)

Open the PDAC breakdown →